about
Fluorescence in situ hybridization analysis of keratinocyte growth factor gene amplification and dispersion in evolution of great apes and humansGenomic structure of the EPHA1 receptor tyrosine kinase geneIdentification of repurposed small molecule drugs for chordoma therapy.Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data.Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines.Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33Corroboration of a familial chordoma locus on chromosome 7q and evidence of genetic heterogeneity using single nucleotide polymorphisms (SNPs).T (brachyury) gene duplication confers major susceptibility to familial chordoma.Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.Molecular characterization of putative chordoma cell linesMolecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell linesCharacterization of T gene sequence variants and germline duplications in familial and sporadic chordoma.Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly.Genotype-phenotype correlation in MYH9-related thrombocytopenia.Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.Developing and sustaining quality improvement partnerships in the VA: the Colorectal Cancer Care Collaborative.A preliminary exploration of college smokers' reactions to nicotine dependence genetic susceptibility feedback.A pathway-based classification of human breast cancer.Quality of nonmetastatic colorectal cancer care in the Department of Veterans Affairs.Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.Genomic signatures to guide the use of chemotherapeutics.Cancer Incidence in HIV-Infected Versus Uninfected Veterans: Comparison of Cancer Registry and ICD-9 Code DiagnosesProactive recruitment of cancer patients' social networks into a smoking cessation trial.Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancerVeterans health administration hepatitis B testing and treatment with anti-CD20 antibody administrationInfluence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer.CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines.Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.A National Survey of Pulmonologists' Views on Low-Dose Computed Tomography Screening for Lung Cancer.BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines.Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks.Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal CancerEffect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer.Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer.Carbonic anhydrase IX in early-stage non-small cell lung cancer.Safety and efficacy of weekly oral oltipraz in chronic smokers.
P50
Q24655504-B7A8B314-1983-4C94-875C-88B2B291E515Q28137653-6AC8BE3B-B0BA-4F38-BDE1-3AD9B04C1D76Q30417586-276235E2-177A-46F0-A238-F77412311F8DQ30784508-7C4EF43C-ECF4-45F6-8E7B-52BBDC6F00DAQ30871677-ECD50E86-CDC2-4494-A1BD-AB57890999EFQ31951687-0C434938-72A8-4F97-AD9C-385E1BE62844Q33271032-F0631FFB-73C2-443E-9AD2-618826C474C9Q33272303-20F99D9B-29A2-4839-BC94-4D3933E7F088Q33273533-0AA85ED7-C3B2-4E42-8694-3D0622ACDCD8Q33273688-42EA5719-3EF5-416C-95AF-67B173CC0255Q33274040-48563C20-F29F-4159-8FF2-8D5B19ED7D05Q33275282-6BAD16DD-58AD-482F-946B-D73CB0A5FF0FQ33275323-DBC2E00B-0201-42F8-BCAD-B5EA0B94768AQ33333969-B41600EF-B693-4AFD-BD2B-CDEA7984739BQ33367809-D7A534BD-8C8A-4C81-93EF-505522EA5FC5Q33397121-CCEF4061-C2B1-4F84-BD1B-3E114ED3E293Q33592629-9DBE788C-4EDA-4A0B-AA41-BAD1D32D8AA6Q33821714-B5973E16-F4D8-4655-8A46-5993872C91F3Q33859531-B8CDCD96-AE3C-4D29-8840-3C076F4354E0Q33990827-E48F4416-94A4-43C6-8EC7-B596B30AE9EFQ34295864-BDC22804-4C9A-4200-BCB6-620135AD428BQ34555834-5054B40E-8D18-4BB6-A132-9A17FAAE0ACDQ34576027-489979EC-5DA5-4C05-9E6E-67B491277EAFQ34849149-D1ADB2BC-09FA-4D37-AC84-12D94CBF22B9Q35013776-4485E90B-2E76-4102-9814-EFE5569CE78FQ35202464-9950C78D-CA3E-4FA6-B058-333C1EC40637Q36472573-03B3B37C-3D3F-4EEC-98A8-BDBD02F7CC42Q36717778-A73A6E64-C5E0-42F7-8C99-593FDD07833EQ36909250-E701848C-E797-4F24-8AC2-B57AD94E2DDEQ37065671-E20A5486-A6B2-43DB-8E09-C736DF56AA38Q38290531-ACA2BC22-600D-4F4B-A381-D2D723243C81Q38357412-494818C7-A28F-4D97-8F5A-BA4B81870459Q38386802-3FBD052E-B86D-4CD0-A4D9-4885046C6634Q38944992-D57C4E75-D25B-49F8-A4D5-D9A87622A499Q39492020-A597BC7C-D98D-416A-A82D-A563F7C744FCQ39519100-120E1888-4B1C-4FA8-9E8C-A309D55ECB61Q41073858-D4C880BD-11C6-4EA5-AEC2-503D241C3965Q41463233-EF62CC5F-BD3E-4300-B731-EA8F13E9497BQ45178467-585A6E7B-A9E3-4A65-BF3D-93075A8BFA06Q46432956-D464F532-0918-4BCD-8C2D-0B5EF80EDB53
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Kelley
@ast
Michael Kelley
@en
Michael Kelley
@es
Michael Kelley
@nl
Michael Kelley
@sl
type
label
Michael Kelley
@ast
Michael Kelley
@en
Michael Kelley
@es
Michael Kelley
@nl
Michael Kelley
@sl
prefLabel
Michael Kelley
@ast
Michael Kelley
@en
Michael Kelley
@es
Michael Kelley
@nl
Michael Kelley
@sl
P108
P106
P1153
35733872700
P21
P31
P496
0000-0001-9523-6080